After Global Blood Therapeutics (GBT) announced 90 day results of its anti-sickling therapeutic, GBT440, Piper Jaffray analyst Joshua Schimmer says the unmet medical need in hemoglobinopathies is "sizable and can accommodate multiple therapeutics." Further, the analyst calls bluebird bio's LentiGlobin unique in that it can potentially enable a full cure. As such, bluebird may be the optimal therapy for more severe patients or those with compliance issues, Schimmer tells investors in a research note. LentiGlobin's penetration into more moderate patients may ultimately depend on GBT440, he adds. The analyst has an Overweight rating on bluebird with a $117 price target. The stock closed yesterday at $45.51. Shares of Global Blood rose 19% to $26.25 in pre-market trading following this morning's data.